Treatment of Endocrine Disorders in the Neuroscience Intensive Care Unit
CRITICAL CARE NEUROLOGY (KN SHETH, SECTION EDITOR)
First Online: 05 January 2014 DOI:
10.1007/s11940-013-0271-4 Cite this article as: Hwang, J.J. & Hwang, D.Y. Curr Treat Options Neurol (2014) 16: 271. doi:10.1007/s11940-013-0271-4 Opinion statement
This review discusses concepts and treatments associated with the most clinically relevant areas of acute endocrine dysfunction amongst patients with common diseases in neuroscience intensive care units (Neuro ICUs). We highlight the following points:
• While a thorough work-up for hyponatremia when it is present is always warranted, subarachnoid hemorrhage (SAH) patients who are in a time window concerning for cerebral vasospasm and who are hyponatremic with high urine output are generally thought to have cerebral salt wasting. These patients are typically treated with a combination of continuous hypertonic saline infusion and fludrocortisone.
• Diabetes insipidus (DI) is often seen in patients fulfilling death by neurological criteria, as well as in patients with recent pituitary surgery and less often in SAH and traumatic brain injury patients who are not brain dead. Patients with DI in the Neuro ICU often cannot drink to thirst and may require a combination of desmopression/vasopressin administration, aggressive fluid repletion, and serum sodium monitoring.
• Diagnosing adrenal insufficiency immediately following pituitary injury is complicated by the fact that the expected atrophy of the adrenal glands, due to lack of a stimulus from pituitary adrenocorticotropic hormone, may take up to 6 weeks to develop. Cosyntropin testing can be falsely normal during this period.
• Both hyperglycemia (glucose >200 mg/dL) and hypoglycemia (glucose <50 mg/dL) are strongly associated with neurological morbidity and mortality in ICUs and should be avoided. Glucose concentrations between 120–160 mg/dL can serve as a reasonable target for insulin infusion protocols.
• There is no data to suggest that treatment of abnormal thyroid function tests in nonthyroidal illness syndrome/sick euthyroid leads to benefits in either mortality or morbidity. True myxedema coma is a rare clinical diagnosis that is treated with intravenous levothyroxine accompanied by stress-dose steroids.
Keywords Endocrine system Intensive care units Subarachnoid hemorrhage Traumatic brain injury Stroke Pituitary apoplexy Brain death Hyperglycemia Hypoglycemia Diabetes insipidus Hyponatremia Inappropriate ADH syndrome Adrenal insufficiency Thyroid Myxedema coma
This article is part of the Topical Collection on
Critical Care Neurology References and Recommended Reading Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med. 2007;356:2064–72.
Kirkman MA, Albert AF, Ibrahim A, Doberenz D. Hyponatremia and brain injury: historical and contemporary perspectives. Neurocrit Care. 2013;18:406–16. This article is a thorough review of hyponatremia as it relates to neurocritical care management.
Wright WL. Sodium and fluid management in acute brain injury. Curr Neurol Neurosci Rep. 2012;12:466–73.
Sviri GE, Feinsod M, Soustiel JF. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage. Clinical and TCD correlations. Stroke. 2000;31:118–22.
Tomida M, Muraki M, Uemura K, Yamasaki K. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998;29:1584–7.
Qureshi AI, Suri MF, Sung GY, et al. Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;50:749–55. discussion 755–46.
Seckl J, Dunger D. Postoperative diabetes insipidus. BMJ. 1989;298:2–3.
McIver B, Connacher A, Whittle I, et al. Adipsic hypothalamic diabetes insipidus after clipping of anterior communicating artery aneurysm. BMJ. 1991;303:1465–7.
Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, et al. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA. 2007;298:1429–38.
Crompton MR. Hypothalamic lesions following the rupture of cerebral berry aneurysms. Brain. 1963;86:301–14.
Klose M, Brennum J, Poulsgaard L, et al. Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clin Endocrinol. 2010;73:95–101. These two papers are amongst the few studies available examining acute pituitary function following subarachnoid hemorrhage.
Parenti G, Cecchi PC, Ragghianti B, et al. Evaluation of the anterior pituitary function in the acute phase after spontaneous subarachnoid hemorrhage. J Endocrinol Invest. 2011;34:361–5. These two papers are amongst the few studies available examining acute pituitary function following subarachnoid hemorrhage.
Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med. 2004;350:1629–38.
Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010;112:681–8.
Hashi K, Takakura K, Sano K, et al. Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage–results of a multi-center controlled double-blind clinical study. No To Shinkei. 1988;40:373–82.
Coronado VG, Xu L, Basavaraju SV, et al. Surveillance for traumatic brain injury-related deaths—United States, 1997-2007. MMWR Surveill Summ. 2011;60:1–32.
Agha A, Rogers B, Sherlock M, et al. Anterior pituitary dysfunction in survivors of traumatic brain injury. J Clin Endocrinol Metab. 2004;89:4929–36.
Agha A, Rogers B, Mylotte D, et al. Neuroendocrine dysfunction in the acute phase of traumatic brain injury. Clin Endocrinol. 2004;60:584–91.
Moro N, Katayama Y, Igarashi T, et al. Hyponatremia in patients with traumatic brain injury: incidence, mechanism, and response to sodium supplementation or retention therapy with hydrocortisone. Surg Neurol. 2007;68:387–93.
Cohan P, Wang C, McArthur DL, et al. Acute secondary adrenal insufficiency after traumatic brain injury: a prospective study. Crit Care Med. 2005;33:2358–66.
Watson NF, Barber JK, Doherty MJ, et al. Does glucocorticoid administration prevent late seizures after head injury? Epilepsia. 2004;45:690–4.
Roberts I, Yates D, Sandercock P, et al. Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomized placebo-controlled trial. Lancet. 2004;364:1321–8.
Edwards P, Arango M, Balica L, et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 2005;365:1957–9.
Agha A, Thornton E, O'Kelly P, et al. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab. 2004;89:5987–92.
Glynn N, Agha A. Which patient requires neuroendocrine assessment following traumatic brain injury, when and how? Clin Endocrinol. 2013;78:17–20. This article contains an in-depth review of the evaluation of acute and chronic pituitary injury following traumatic brain injury.
Hensen J, Henig A, Fahlbusch R, et al. Prevalence, predictors and patterns of postoperative polyuria and hyponatraemia in the immediate course after transsphenoidal surgery for pituitary adenomas. Clin Endocrinol. 1999;50:431–9.
Kronenberg H, Williams RH. Williams textbook of endocrinology. 11th ed. Philadelphia, PA: Saunders/Elsevier; 2008.
Smith M. Physiologic changes during brain stem death–lessons for management of the organ donor. J Heart Lung Transplant. 2004;23:S217–22.
Ranasinghe AM, Bonser RS. Endocrine changes in brain death and transplantation. Best Pract Res Clin Endocrinol Metab. 2011;25:799–812.
Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg. 2008;85:278–86. discussion 286.
Nicolas-Robin A, Barouk JD, Amour J, et al. Hydrocortisone supplementation enhances hemodynamic stability in brain-dead patients. Anesthesiology. 2010;112:1204–10.
Venkateswaran RV, Dronavalli V, Lambert PA, et al. The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation. 2009;88:582–8.
Guesde R, Barrou B, Leblanc I, et al. Administration of desmopressin in brain-dead donors and renal function in kidney recipients. Lancet. 1998;352:1178–81.
Howlett TA, Keogh AM, Perry L, et al. Anterior and posterior pituitary function in brain-stem-dead donors. A possible role for hormonal replacement therapy. Transplantation. 1989;47:828–34.
Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? Transplantation. 1992;54:851–7.
Randell TT, Hockerstedt KA. Triiodothyronine treatment in brain-dead multiorgan donors—a controlled study. Transplantation. 1992;54:736–8.
Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83:41–7.
Kramer AH, Roberts DJ, Zygun DA. Optimal glycemic control in neurocritical care patients: a systematic review and meta-analysis. Crit Care. 2012;16:R203. This review and meta-analysis addresses management of glycemic control specifically with regards to neurocritical care patients.
Griesdale DE, Tremblay MH, McEwen J, Chittock DR. Glucose control and mortality in patients with severe traumatic brain injury. Neurocrit Care. 2009;11:311–6.
Dorhout Mees SM, van Dijk GW, Algra A, et al. Glucose levels and outcome after subarachnoid hemorrhage. Neurology. 2003;61:1132–3.
Badjatia N, Topcuoglu MA, Buonanno FS, et al. Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage. Crit Care Med. 2005;33:1603–9.
Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyperglycemia on clinical course after intracerebral hemorrhage. Neurology. 2003;61:1351–6.
van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359–67.
Investigators N-SS, Finfer S, Chittock DR, et al. Intensive vs. conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–97.
Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125–39.
Arabi YM, Dabbagh OC, Tamim HM, et al. Intensive vs. conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Crit Care Med. 2008;36:3190–7.
Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008;300:933–44.
Ajaz F, Kudva YC, Erwin PJ. Residual dysphasia after severe hypoglycemia in a patient with immune-mediated primary adrenal insufficiency and type 1 diabetes mellitus: case report and systematic review of the literature. Endocr Pract. 2007;13:384–8.
Kurabayashi H, Kubota K, Tamura K, et al. Motor aphasia due to prolonged hypoglycaemic coma in a patient with insulin-dependent diabetes mellitus. J Int Med Res. 1996;24:487–91.
Auer RN, Wieloch T, Olsson Y, Siesjo BK. The distribution of hypoglycemic brain damage. Acta Neuropathol. 1984;64:177–91.
Guettier JM, Gorden P. Hypoglycemia. Endocrinol Metab Clin North Am. 2006;35:753–66, viii–ix.
Service FJ. Hypoglycemia. Endocrinol Metab Clin North Am. 1997;26:937–55.
Arem R, Wiener GJ, Kaplan SG, et al. Reduced tissue thyroid hormone levels in fatal illness. Metabolism. 1993;42:1102–8.
Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med. 1999;159:658–65.
Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem. 1987;33:1391–6.
Stathatos N, Levetan C, Burman KD, Wartofsky L. The controversy of the treatment of critically ill patients with thyroid hormone. Best Pract Res Clin Endocrinol Metab. 2001;15:465–78.
Slag MF, Morley JE, Elson MK, et al. Free thyroxine levels in critically ill patients. A comparison of currently available assays. JAMA. 1981;246:2702–6.
Slag MF, Morley JE, Elson MK, et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA. 1981;245:43–5.
Chinga-Alayo E, Villena J, Evans AT, Zimic M. Thyroid hormone levels improve the prediction of mortality among patients admitted to the intensive care unit. Intensive Care Med. 2005;31:1356–61.
Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63:1–8.
Becker RA, Vaughan GM, Ziegler MG, et al. Hypermetabolic low triiodothyronine syndrome of burn injury. Crit Care Med. 1982;10:870–5.
Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery. N Engl J Med. 1995;333:1522–7.
Wartofsky L. Myxedema coma. Endocrinol Metab Clin North Am. 2006;35:687–98, vii–viii.
Jellinek EH. Fits, faints, coma, and dementia in myxoedema. Lancet. 1962;2:1010–2.
Edwards GA. Neurologic manifestations of myxedema. Med Times. 1968;96:1125–30.
Nieman EA. The electroencephalogram in myxoedema coma: clinical and electroencephalographic study of three cases. BMJ. 1959;1:1204–8.
River Y, Zelig O. Triphasic waves in myxedema coma. Clin Electroencephalogr. 1993;24:146–50.
Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.
Human T, Onuoha A, Diringer M, Dhar R. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury. J Crit Care. 2012;27(745):e741–5.
Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care. 2009;11:14–9.
PubMedCentral PubMed CrossRef
Wright WL, Asbury WH, Gilmore JL, Samuels OB. Conivaptan for hyponatremia in the neurocritical care unit. Neurocrit Care. 2009;11:6–13.
Woo CH, Rao VA, Sheridan W, Flint AC. Performance characteristics of a sliding-scale hypertonic saline infusion protocol for the treatment of acute neurologic hyponatremia. Neurocrit Care. 2009;11:228–34.
Shetty S, Inzucchi SE, Goldberg PA, et al. Adapting to the new consensus guidelines for managing hyperglycemia during critical illness: the updated Yale insulin infusion protocol. Endocr Pract. 2012;18:363–70.
Kunjan K, Lloyd FP. Automated blood sampling and glucose sensing in critical care settings. J Diabetes Sci Technol. 2008;2:194–200.
PubMedCentral PubMed CrossRef
Skjaervold NK, Solligard E, Hjelme DR, Aadahl P. Continuous measurement of blood glucose: validation of a new intravascular sensor. Anesthesiology. 2011;114:120–5.
Holzinger U, Warszawska J, Kitzberger R, et al. Real-time continuous glucose monitoring in critically ill patients: a prospective randomized trial. Diabetes Care. 2010;33:467–72.
Brunner R, Kitzberger R, Miehsler W, et al. Accuracy and reliability of a subcutaneous continuous glucose-monitoring system in critically ill patients. Crit Care Med. 2011;39:659–64.
Goldberg PA, Siegel MD, Russell RR, et al. Experience with the continuous glucose monitoring system in a medical intensive care unit. Diabetes Technol Ther. 2004;6:339–47.
Rabiee A, Andreasik V, Abu-Hamdah R, et al. Numerical and clinical accuracy of a continuous glucose monitoring system during intravenous insulin therapy in the surgical and burn intensive care units. J Diabetes Sci Technol. 2009;3:951–9.
PubMedCentral PubMed CrossRef
Yamashita K, Okabayashi T, Yokoyama T, et al. Accuracy and reliability of continuous blood glucose monitor in postsurgical patients. Acta Anaesthesiol Scand. 2009;53:66–71.
Inzucchi SE, Kosiborod M. Continuous glucose monitoring during critical care. Anesthesiology. 2011;114:18–9.
PubMed CrossRef Copyright information
© Springer Science+Business Media New York 2013